Investigational drug · Phase 3
Obrixtamig
Also called: BI 764532
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
14
Any phase or sponsor naming "Obrixtamig"
First trial start
2023
Oct 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Obrixtamig", any sponsor or status.
Conditions studied
As listed on its trial records.
- Small Cell Lung Cancer
- Large Cell Neuroendocrine Lung Carcinoma
- Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
- Small Cell Lung Carcinoma
- Neuroendocrine Neoplasms
- Extra-pulmonary Neuroendocrine Carcinoma
- Advanced Cancer
- Small Cell Lung Cancer (SCLC)
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Approved drugs for the same conditions: Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Obrixtamig" as an intervention, largest first.
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07472517 · 670 participants (planned) · Start Apr 13, 2026 · Primary completion Sep 9, 2028
Drug: obrixtamig; atezolizumab and 2 more · For: Small Cell Lung Cancer (SCLC); Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sites: Mobile, Alabama; Little Rock, Arkansas; Hialeah, Florida · 242 sites in all
- DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard ChemotherapyPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07544654 · 390 participants (planned) · Start Jul 10, 2026 · Primary completion Dec 13, 2029
Drug: Obrixtamig; Carboplatin and 1 more · For: Extrapulmonary Neuroendocrine Cancer (epNEC)
Sites: Scottsdale, Arizona; Duarte, California; San Francisco, California · 170 sites in all
- A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT04429087 · 306 participants · Start Jul 29, 2020 · Primary completion Aug 31, 2026
Drug: Obrixtamig - parenteral 1; Obrixtamig - parenteral 2 · For: Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
Sites: Atlanta, Georgia; Baltimore, Maryland; St Louis, Missouri · 12 sites in all
- DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine CancersPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT05882058 · 204 participants (planned) · Start Oct 13, 2023 · Primary completion Dec 17, 2027
Drug: BI 764532, dose 1; BI 764532, dose 2 · For: Small Cell Lung Carcinoma; Neuroendocrine Neoplasms; Extra-pulmonary Neuroendocrine Carcinoma
Sites: Mobile, Alabama; Phoenix, Arizona; Los Angeles, California · 59 sites in all
- A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the LungNot yet recruiting
Technische Universität DresdenAcademic, hospital or other
NCT07561645 · 75 participants (planned) · Start Sep 2026 · Primary completion Apr 2032
Drug: Obrixtamig · For: Large Cell Neuroendocrine Carcinoma of the Lung
- DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent ChemotherapyActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT05990738 · 69 participants · Start Feb 14, 2024 · Primary completion Mar 30, 2027
Drug: BI 764532; Topotecan and 1 more · For: Small Cell Lung Carcinoma (SCLC)
Sites: Washington D.C., District of Columbia; Jacksonville, Florida; Miami, Florida · 14 sites in all
- A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With ObrixtamigPivotal-lookingNot yet recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07929051 · 68 participants (planned) · Start Mar 4, 2027 · Primary completion Jul 3, 2028
Drug: Obrixtamig; Ezabenlimab and 3 more · For: Advanced Cancer
Sites: Ghent, Belgium; Bordeaux, France; Bron, France · 15 sites in all
- DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine CancersActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06132113 · 65 participants · Start Jan 22, 2024 · Primary completion Oct 9, 2027
Drug: BI 764532; Carboplatin and 2 more · For: Neuroendocrine Neoplasms
Sites: Miami, Florida; Atlanta, Georgia; Chicago, Illinois · 21 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT07707895 · 60 participants (planned) · Start Nov 3, 2026 · Primary completion Apr 26, 2030
Drug: Obrixtamig; ZL-1310 and 1 more · For: Small Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma; Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology and 1 more
Sites: Washington D.C., District of Columbia; Tampa, Florida; Lexington, Kentucky · 28 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT07843940 · 55 participants (planned) · Start Oct 1, 2026 · Primary completion Apr 17, 2030
Drug: Obrixtamig; Pumitamig and 2 more · For: Extensive-stage Small Cell Lung Carcinoma; Advanced Small Cell Lung Cancer
Sites: Miami, Florida; Boston, Massachusetts; East Brunswick, New Jersey · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- T-cell engagers in small-cell lung cancer: current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation Workshop.
Meyer ML, Peters S, Ahn MJ, et al. · Cancer Treat Rev 2026
- Emerging therapies and translational advances in small cell lung cancer: Overcoming resistance.
Nishii Y, Yamaguchi Y, Yoshida T · Respir Investig 2026
- Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.
Wermke M, Gambardella V, Kuboki Y, et al. · J Clin Oncol 2025
- Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
Wermke M, Felip E, Gambardella V, et al. · Future Oncol 2022
Also in development for Small Cell Lung Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- ZG006Phase 38 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Neuroendocrine Carcinoma, Small Cell Lung Cancer, Solid Tumor
- ABBV-706Phase 34 trials
AbbVie · Small Cell Lung Cancer, Extensive Stage-Small Cell Lung Cancer (ES-SCLC), Extensive Stage-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.